Skip to main content
Premium Trial:

Request an Annual Quote

Molecular Assemblies Raises $12.2M in Series A Financing

NEW YORK – Molecular Assemblies today announced it has raised $12.2 million in Series A financing.

The iSelect Fund led the round, joined by existing investors Agilent Technologies, Alexandria Venture Investments, Keshif Ventures. San Diego-based Molecular Assemblies said it will use the proceeds to advance its enzymatic DNA synthesis technology.

"Enzymatic DNA synthesis is the optimal way to create a cost-effective, sustainable, and scalable integrated system that stores and reads information in DNA," Mike Kime, managing director, iSelect Fund, said in a statement. "With a proprietary technology position, Molecular Assemblies' novel enzymatic DNA synthesis platform has the potential to fundamentally transform how we create DNA on demand to enable breakthroughs in life sciences, information storage, synthetic biology, and electronics."

Molecular Assemblies has created a two-step enzymatic DNA synthesis process that can deliver long, pure DNA without a template, on demand. It's one of several teams that are working on enzymatic DNA synthesis methods, including Ansa Biotechnologies and DNA Script. An enzymatic process, in theory, would allow longer oligos and would be less likely to damage the DNA than established chemical methods. In 2018, the firm claimed to be able to store and retrieve digital information in DNA using its process.

"Our ability to reliably, affordably, and sustainably produce long, high-quality DNA can accelerate life science research and transform the information storage industry by enabling integrated systems that can write and read DNA data," Molecular Assemblies President and CEO Michael Kamdar said in a statement.

The firm raised $2.3 million in seed funding in 2016 from Agilent, Cavendish Impact Capital Fund, Eleven Two Capital, Keshif Ventures, Genomics Investment Syndicate, Newport Holdings, and Alexandria Venture Investments.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.